NCT01980316

Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting

Phase 4 Study of Argatroban for Preventing Restenosis After Extracranial Vertebral Artery Stenting

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 114 (actual)
• Sponsor: Xinfeng Liu · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post percutaneous coronary intervention could potentially prevent reocclusion. But there has no study on large sample of argatroban treated restenosis vertebral artery stenting. This study will test the safety and efficacy of the argatroban on prevent Occlusion and Restenosis in patients with Extracranial vertebral Artery Stenting.

Detailed description

The risk of restenosis post intracranial and extracranial artery stenting is 20-40%, therefore, in the past, aspirin and clopidogrel were performed as anticoagulant therapy post stenting.But this treatment had limited effectiveness upon restenosis. Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post PCI could potentially prevent reocclusion. But there has no study on large sample of argatroban treated Occlusion and Restenosis Extracranial vertebral Artery Stenting. This study will test the safety and efficacy of the argatroban on prevent Occlusion and Restenosis in patients with Extracranial vertebral Artery Stenting.

Conditions

• CVD

Interventions

Type	Name	Description
DRUG	Argatroban	Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
DRUG	non-argatroban treated group	Patients in control group will receive Unfractionated heparin treatment

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-08-01
• Completion: 2013-07-01
• First posted: 2013-11-08
• Last updated: 2015-10-23

Locations

1 site across 1 country: China